NPY mRNA and NPY-LI have recently been detected in rat megakaryocytes and platelets6x7 as well as in preparations of rat mononuclear blood cells.7 In particular, high levels of NPY mRNA were found in bone marrow of certain strains of autoimmune mice that develop B-cell lymphoproliferative disorders6 However, no or very low levels of NPY mRNA and NPY-LI were detected in bone marrow, spleen, or platelets of healthy adult human^.^
N originally isolated from pig brain,' highly conserved in mammals,2 and found throughout the human central and peripheral nervous systems where it functions as a neurotransmitter or ne~romodulator.3~~ High concentrations of NPY-like immunoreactivity (NPY-LI) have also been found in neuroendocrine tumor^.^ NPY mRNA and NPY-LI have recently been detected in rat megakaryocytes and platelets6x7 as well as in preparations of rat mononuclear blood cells.7 In particular, high levels of NPY mRNA were found in bone marrow of certain strains of autoimmune mice that develop B-cell lymphoproliferative disorders6 However, no or very low levels of NPY mRNA and NPY-LI were detected in bone marrow, spleen, or platelets of healthy adult human^.^
We have recently reported high plasma concentrations of NPY-LI in children with neuroblastoma.8 When analyzing NPY in controls for that study, we found high plasma NPY-LI (P-NPY-LI) in some children with leukemia. In this report we have extended this finding and performed a prospective study of P-NPY-LI in children with acute leukemia. In addition, we have investigated the source of increased systemic NPY in these children by examining leukemic bone marrow for NPY mRNA using Northern blot and in situ hybridization. Furthermore, a possible correlation of elevated P-NPY-LI with clinical classification, leukemic immunophenotype, and prognosis in pediatric leukemia was analyzed.
MATERIALS AND METHODS

Patient material.
A series of 51 consecutive children with acute leukemia was investigated for NPY in plasma (Table 1) . They were diagnosed using morphologic criteria of the French-AmericanBritish (FAB) Cooperative Group9 and classified using established risk criterias'O (Table 1) into acute lymphoblastic leukemia of standard risk (ALL-SR), intermediate risk (ALL-IR), high risk (ALL-HR), or acute nonlymphocytic leukemia (ANLL). Uniform treatment was given according to national protocols (ALL-SR: Swedish Pediatric Leukemia Group), international protocols (ALL-IR and ALL-HR; German Cooperative Study, BFM-83), and Nordic protocols (ANLL; Nordic Society of Paediatric Haematology and Oncology). Fifty-one healthy children admitted for elective surgery matched for age and sex served as controls (Table  1) . P-NPY-LI was compared with the upper age-adjusted reference limit obtained from a study comprising 112 healthy children (P.K., O.B., E.T.: unpublished observations, 1992). Children with leukemia were observed for 2 to 46 months from diagnosis. Bone marrow or peripheral lymphoblasts from eight children with acute leukemia were studied for NPY mRNA (Table 2) .
Venous blood was collected from children with acute leukemia at diagnosis and matched healthy controls in prechilled heparinized tubes, transported in ice bath, and centrifugated (1,500g 10 minutes, +4"C) within 30 minutes." Plasma was stored at -20°C until analysis.
Bone marrow aspirates were obtained from the posterior iliac crest and immediately fresh frozen at -70°C. Peripheral malignant lymphoblasts were obtained from venous blood of one child and quick frozen (-70°C) for subsequent extraction of RNA.
NPY-LI was analyzed in extracted plasma by a competitive radioimmunoassay using an antiserum raised in a rabbit as previously described.'* Northern blot analysis of NPY mRNA. Total cellular RNA was prepared from bone marrow and peripheral lymphoblasts, fractionated in parallel on a denaturing agarose gel, blotted onto nitrocellulose membranes, and hybridized to a 32P-labeled human NPY cDNA probeI3 as previously described? Polyadenylated RNA from rat cerebral cortex was run in parallel as a positive hybridization control.
Bone marrow smears were prepared at diagnosis on poly-lysine (50 kg/mL) coated slides, fixed in 4% paraformaldehyde, and hybridized to a 294-bp AvaI-EcoRI fragSample handling.
Radioimmunoassay for NPY.
In situ hybridization. ment from a human NPY cDNA clone. As a hybridization control, a 600-bp AluI DNA fragment including the second exon of the human preprocholecystokinin (CCK) gene14 was used. The probes were labeled by nick translation with deoxyadenosine ~' [ ( u -~~S ] tiotriphosphate (d3% dATP) to a specific activity of approximately 3 x lo8 cpmikg. Hybridization was performed at 42°C for 14 hours in 50% formamide, 4X SSC (1X SSC = 0.15 mol/L NaCl, 15 mmol/L sodium citrate), 1X Denhardt's solution, 10% dextran sulfate, 0.25 mg/mL yeast tRNA, 0.5 mg/mL sheared salmon sperm DNA, 50 mmol/L dithiothreitol (DTT) and 5 x lo6 cpm/mL of the probe. After hybridization the smears were rinsed, washed 4 X 15 minutes at 55°C in 1X SSC, and air dried. The smears were dipped in Kodak NTB-2 photo emulsion (Eastman Kodak, Rochester, NY) diluted 1:l in water and exposed for 5 weeks at -2O"C, developed, fixed, and counterstained with hematoxylin-eosin. The smears were photographed in a Leitz Ortholux microscope.
Leukemic blast cells were obtained from bone marrow at diagnosis and immunophenotyped using flow cytometry and a panel of monoclonal antibodies (MoAbs) as previously described.I5 ALL was classified as T-cell (two of CD2+, CD5+, CD7+), B-cell (surface Ig+), or B-cell precursor (BCP; sIg-, HLA-DR+, CD19+, CD10'). The bone marrow was considered positive if more than 20% of cells expressed the antigen. For Immunophenolyping. analytical purposes, BCP ALL was further subdivided as CALLA+ (> 20% but < 50% CD10+) and CALLA++ (> 50% CD10+).I6
The median and interquartile range (median: lower quartile-upper quartile) were used as measures of central tendency and variation, respectively, throughout the study. Statistical significance was calculated using Kruskal-Wallis analysis of variance for several groups or Wilcoxon Mann-Whitney test when two groups were ~0 m p a r e d . l~ Event-free survival (EFS) and survival probabilities were calculated using the product limit method of Kaplan-Meierls and compared using the MantelHanszel log-rank test.I9
The present study was approved by the ethical committee of the Karolinska Institute.
Statistical analysis.
Ethical approval.
RESULTS
P-NPY-LI was increased at diagnosis (P < .001) in the group of children with acute leukemia as compared with a group of matched healthy controls ( Table  1) . P-NPY-LI was found to be elevated in 31 of 51 leukemic children (61%) as compared with the upper age-adjusted reference limit ( Table 1) .
The P-NPY-LI concentrations found in children with ALL-SR and ALL-IR were higher (P < .001 to P < .005)
when compared to children with ALL-HR and ANLL (Table 1) . A favorable risk classification (ALL-SR or ALL-IR) was associated with a greater proportion of elevated P-NPY-LI (28 of 31) compared to those with unfavorable risk classification (ALL-HR or ANLL, 3 of 20,
Children with elevated P-NPY-LI at diagnosis were monitored with serial determinations after induction of chemotherapy. At remission, P-NPY-LI was normalized in all children (19: 16 to 32 pmol/L). In two children with elevated P-NPY-LI at diagnosis, P-NPY-LI was analyzed at relapse. A second increase was detected in one child while the other had a normal concentration at relapse. Interestingly, this second child with a BCP ALL-SR at diagnosis showed a decreased portion of CD10+ blasts and an unfavorable chromosomal translocation, t(9;22), at relapse that was not detected at diagnosis.zo P-NPY-LI at diagnosis correlated well to differentiation found at immunophenotyping. All children with elevated P-NPY-LI (n = 31) had a B-cell precursor ALL (Fig 1) . No children with T-cell ALL, B-cell ALL, or ANLL (n = 11) showed elevated P-NPY-LI at diagnosis (P < .001, Fisher's exact test). Children with a CALLA-positive (CD10+) leukemia (n = 33) had higher P-NPY-LI (280: 185 to 615 pmol/L) when compared with both all CALLA-(43: 28 to 76 pmol/L, P < .001) and CALLA-BCP ALL (33: 26 to 155 pmol/L, P < .01). Furthermore, children considered as CALLA++ (62% to 98% CD10+ cells, n = 28) had higher P-NPY-LI than all other groups (P < .001), including CALLA+ (20% to 41% CDlO+, n = 5) (Fig 1) . No correlation was found between P-NPY-LI and the platelet count at diagnosis (R = .12, data not shown).
Sixteen children with unfavorable outcome (death or relapse) showed lower P-NPY-LI at diagnosis (56: 32 to 180 pmol/L) than 30 children who remained in first remission after more than 12 months of follow-up (270 126 to 620 pmol/L,P < .Ol). The 31 children with elevated age-adjusted P-NPY-LI at diagnosis had better outcome compared to the 20 children with normal P-NPY-LI (79.4% v 34.6% EFS probability, P < .001, Fig 2) . When restricting analysis to children with ALL (n = 46) or B-line ALL (n = 41), we still found better outcome (EFS) for those with elevated P-NPY-LI (P < .01 and P < .05, respectively). In the 40 children with BCP ALL, those with elevated P-NPY-LI had significantly better survival (93.2% v 32.1%, P < .05) and a tendency toward better EFS (79.4% v 51.9%, P = .09) compared to children with BCP ALL and normal P-NPY-LI. Among 31 children with elevated age-adjusted P-NPY-LI at diagnosis, there are two in second remission (3 and 13 months after relapse, respectively) and one toxic death while only one has died from leukemia.
NPY in
NPY mRNA in bone marrow and peripheral lymphoblasts. Using Northern blot analysis, NPY mRNA was detected in samples from five children of eight tested. A 0.8-kb NPY mRNA was detected in total cellular RNA prepared from four of seven bone marrow aspirates (Fig 3) . NPY mRNA was also detected in peripheral lymphoblasts from one child 2, Fig 3) . All children who showed the presence of NPY mRNA had a B-cell precursor immunophenotype. Large differences were observed between the four children with NPY mRNA in their bone marrow. The two with a favorable clinical risk classification and CALLA++ (JP and SF) showed approximately 10 times higher amounts of NPY mRNA in the bone marrow than the other two (NF and MW). NPY mRNAwas not detected in leukemic bone marrow of T-cell differentiation (VS and MH) or in bone marrow at remission (ML). In one child (MW) there was detectable NPY mRNA in bone marrow at remission, but in significantly lower amounts than at diagnosis (data not shown).
Bone marrow smears from one child with CALLA++ BCP ALL (JP, Table 2 ), positive for NPY mRNA in the Northern blot analysis, were analyzed by in situ hybridization for NPY mRNA. The labeled cells were identified as leukemic lymphoblasts and no specific signal was seen in other cell types (Fig 4) . A significant proportion, but not all, of the leukemic lymphoblasts were labeled. No labeled cells were seen after hybridization with a probe specific for the human CCK gene (data not shown). The same probe did not show CCK mRNA in the bone marrow of any of the patients by Northern blot analysis and therefore was used as a specific control for the in situ hybridization.
DISCUSSION
The present study demonstrates elevated concentrations of plasma NPY (analyzed as P-NPY-LI) in acute pediatric leukemia. Furthermore, elevated P-NPY-LI was found mainly in children with a favorable risk classification, and only in those with B-cell precursor ALL. A consistent and rapid normalization of P-NPY-LI after initiation of chemotherapy implied tumoral origin of increased systemic NPY-LI, which was supported by the evidence for NPY synthesis in leukemic bone marrow and peripheral lymphoblasts of B-cell precursor ALL.
Elevated P-NPY-LI was closely related to clinical classification, differentiation, and outcome in 51 children monitored for 2 to 46 months. Elevated P-NPY-LI was only found in children with BCP ALL. The highest concentrations of P-NPY-LI were found in children with a high percentage of CALLA-positive cells in the bone marrow (Fig l) , but some children with earlier B-cell precursor differentiation (HLA-DR+, CD19+, and CDlO-) also showed elevated P-NPY-LI. P-NPY-LI was, on the other hand, normal in the only child investigated with B-cell ALL. Elevated P-NPY-LI was significantly associated with a favorable outcome in children with leukemia (Fig 2) .
During the last few decades, introduction of effective multidrug chemotherapy has made the cure of childhood leukemia possible.21,22 Furthermore, identification of prognostic factors, including the immunophenotype, has made it possible to prospectively predict risk of relapse and, therefore, to design risk-based therapy to optimize the risk benefit ratio of treatment for children with ALL.21-23 The identification of additional prognostic factors may further optimize therapy in these children, aiming both at insion.
creased survival for those with leukemia of poor risk as well polyadenylated RNA) , bone marrow and peripheral lymphoblasts from children with leukemia (total cellular RNA), were electrophoresed in l% agarose gels containing 0.7% formaldehyde and 0.1 pg ethidium bromide. After electrophoresis gels were examined under UV light to ensure equal amounts of RNA in each sample. RNA was transferred to nitrocellulose filters and hybridized to a human NPY cDNA probe" labeled with oJ*P-dCTP. Details on children studied in Table 2 .
kb+
as diminished side effects for children with "good risk leukemia." In addition, a marker in plasma indicating the differentiation of the leukemic lymphoblasts could provide a useful complement to current immunophenotyping and make classification possible when flow cytometry fails for some reason. Whether P-NPY-LI is an indcpendent prognostic factor in pediatric leukemia or merely a marker of Btell precursor differentiation remains to be studied in larger patient materials. In this limited series, P-NPY-LI as a marker for B-ccll precursor ALL had a sensitivity of 77.5% (31 of 40) and a specificity of 100% (1 1 of 11) . From these results we may suggest P-NPY-LI as a marker for BCP ALL while the significance of P-NPY-LI as an independent prognostic indicator is uncertain.
NPY synthesis was demonstrated in human leukemic bone marrow and peripheral malignant lymphoblasts of B-cell precursor ALL by RNA blot analysis (Fig 3) . Furthermore, in situ hybridization showed NPY synthesis in leukemic lymphoblasts (Fig 4) . NPY mRNA or NPY-LI have not . previously been detected in human bone marrow, but was recently found in rat bone marrow6 and in a preparation of rat mononuclear cells.' The highest concentrations of NPY-LI and NPY mRNA in these studies were found in megakaryocytes and platelet^.".^ However, no correlation between P-NPY-LI and platelet count was found in the present study, indicating that platelets were not the source of increased P-NPY-LI in children with leukemia. Interestingly, high levels of NPY mRNA and peptide were also found in bone marrow of autoimmune mice with B-cell lymphoproliferative disorders? These results, in conjunction with our present finding of stage-specific expression of NPY in malignant B-cell precursors (Figs 1 and 3) , imply a role of NPY during normal Btell development and/or pathologic disorders of B-line cells. Recently, NPY was shown to increase the adhesiveness of leukocytes to endothelial suggesting a role of this peptide in cell adhesion in the hematopoietic system. Systemic effects on the blood pressure could be expected because similar concentrations of P-NPY-LI to those reported here have been detected in pheochromocytoma patients during peroperative hypertension.z NPY was suggested to play a role in hypertension found in those patientsz However, in the present material only one infant, with normal P-NPY-LI, presented with hypertension. This child, with ANLL, was one of the three children with elevated catecholamine metabolites in urine (all with normal P-NPY-LI). These findings are in accordance with our previous findings in children with neuroblastoma that were normotensive despite elevated P-NPY-Ll?. 26 In plasma and tumor tissue from neuroblastoma patients, high amounts of smaller NPY fragments were foundz6 that may, as previously suppress the vasoconstrictive effect of intact NPY.
I
Combined with our previous findings on NPY in neuroblastoma$.*6 the results presented in this report warrant studies on other gene products expressed in common between pediatric neuroblastoma and B-cell precursor ALL as well as developing cells of the neural and hematouse only. MYCN (N-myc) , of importance for prognosis and tumor growth in ne~roblastoma,2~,~~ appears to be expressed in cells of early B differentiation but not in mature B cells or plasma cells?* Furthermore, it has been proposed that MYC activation may be of significance in the evolution of B-cell precursor leukemia.32 Nerve growth factor (NGF), inducing differentiation in neural cells and regulating NPY synthesis in PC12 has been shown to stimulate DNA synthesis and Ig secretion in B ~e l l s . 3~ NGF receptors appear to be expressed both in leukocytes and several immune organs of different species including the chicken bursa of Fabrici~s?~ the primary tissue for B-cell production, as well as on human B cells of mature differentiati~n.~~ Hence, in addition to NPY, gene products important for cell growth and differentiation appear to be expressed in common between the hematopoietic and nervous systems. Future studies on these gene products may provide further insight into hematopoietic cell development and leukemic cell biology.
Our finding of a close relation between NPY and expression of CALLA (CD10) motivates further studies on NPY-CALLA interactions. It was recently demonstrated that CALLA is identical to a zinc metalloprotease, neutral endopeptidase 24.11.37,38 CALLA hydrolyzes biologically active peptides inducing migration and aggregation of neutrophils expressing CALLA? 8 In summary, our study shows that NPY is synthesized by leukemic lymphoblasts of B-cell precursor differentiation, suggesting a role of NPY in the human hematopoietic system. Furthermore, a high concentration of plasma NPY-LI is associated with expression of CALLA (CD10) in a subset of B-cell precursor ALL with a favorable clinical risk classification. Elevated plasma NPY-LI at diagnosis appears to correlate with a favorable outcome in pediatric leukemia. Finally, we suggest that elevated P-NPY-LI could be used as an indicator of B-cell precursor differentiation in children with acute leukemia.
